Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition
Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1...
Gespeichert in:
Veröffentlicht in: | OncoTargets and therapy 2019-01, Vol.12, p.495-508 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 508 |
---|---|
container_issue | |
container_start_page | 495 |
container_title | OncoTargets and therapy |
container_volume | 12 |
creator | Wu, Junfeng Li, Wei Ning, Jinzhuo Yu, Weimin Rao, Ting Cheng, Fan |
description | Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer.
Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed.
UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities.
These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer. |
doi_str_mv | 10.2147/OTT.S183940 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6331189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A687140483</galeid><sourcerecordid>A687140483</sourcerecordid><originalsourceid>FETCH-LOGICAL-c615t-da6741bab6b53d012d95a6f8b0648eb8190b8702196b7f3777dcea2e19e638df3</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7rp65b0EBBGkYz7aJL0RhkFXYXBhnb0OaXPaZukkY5IK-3_8oWbccZ0RyUUOJ895k3PyFsVLgheUVOL91Waz-EYkayr8qDgnRMiSNww_PorPimcx3mLMuaTV0-KM5YgTKs-Ln2vvBuS867yxObr-ukQ3qyVBSYcBUkRbe13Wkpb1DmlnUOddCradE0SUPEojoF3wQ4AYrXe_ERPmAeWEjUm7DpDvUTtpYyCgbp_IG0xTLh-Dn4cRLTeXotyCsTqBQXpOfjfq4Q5ZN9rWpiz7vHjS6ynCi8N-Udx8-rhZfS7XV5dfVst12XFSp9JoLirS6pa3NTOYUNPUmveyxbyS0ErS4FYKTEnDW9EzIYTpQFMgDXAmTc8uig_3uru5zQ_qIPeqJ7ULdqvDnfLaqtMTZ0c1-B-KM0aIbLLA24NA8N9niEltbdx3qx34OSpKRMOauiYko6__QW_9HFxuT1FKMyNr3PylBj2Bsq73-d5uL6qWXApS4UqyTC3-Q-VlYGvzj0Fvc_6k4M1RwQh6SmP007wfdjwF392DXfAxBugfhkGw2rtPZfepg_sy_ep4fg_sH7uxX9FN1Js</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2229558509</pqid></control><display><type>article</type><title>Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wu, Junfeng ; Li, Wei ; Ning, Jinzhuo ; Yu, Weimin ; Rao, Ting ; Cheng, Fan</creator><creatorcontrib>Wu, Junfeng ; Li, Wei ; Ning, Jinzhuo ; Yu, Weimin ; Rao, Ting ; Cheng, Fan</creatorcontrib><description>Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer.
Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed.
UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities.
These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S183940</identifier><identifier>PMID: 30666128</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Antisense RNA ; Apoptosis ; Autophagy ; Biomarkers ; Bladder cancer ; Cancer ; Cancer therapies ; Cell cycle ; Cell growth ; Colorectal cancer ; Development and progression ; Drug resistance ; Drug therapy ; Health aspects ; Health risk assessment ; Immunohistochemistry ; Liver cancer ; Oncology, Experimental ; Original Research ; Polymerase chain reaction ; Tumorigenesis</subject><ispartof>OncoTargets and therapy, 2019-01, Vol.12, p.495-508</ispartof><rights>COPYRIGHT 2019 Dove Medical Press Limited</rights><rights>2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Wu et al. This work is published and licensed by Dove Medical Press Limited 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c615t-da6741bab6b53d012d95a6f8b0648eb8190b8702196b7f3777dcea2e19e638df3</citedby><orcidid>0000-0003-3691-5950</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331189/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331189/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3860,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30666128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Junfeng</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Ning, Jinzhuo</creatorcontrib><creatorcontrib>Yu, Weimin</creatorcontrib><creatorcontrib>Rao, Ting</creatorcontrib><creatorcontrib>Cheng, Fan</creatorcontrib><title>Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer.
Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed.
UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities.
These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer.</description><subject>Antisense RNA</subject><subject>Apoptosis</subject><subject>Autophagy</subject><subject>Biomarkers</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Colorectal cancer</subject><subject>Development and progression</subject><subject>Drug resistance</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Health risk assessment</subject><subject>Immunohistochemistry</subject><subject>Liver cancer</subject><subject>Oncology, Experimental</subject><subject>Original Research</subject><subject>Polymerase chain reaction</subject><subject>Tumorigenesis</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkl2L1DAUhoso7rp65b0EBBGkYz7aJL0RhkFXYXBhnb0OaXPaZukkY5IK-3_8oWbccZ0RyUUOJ895k3PyFsVLgheUVOL91Waz-EYkayr8qDgnRMiSNww_PorPimcx3mLMuaTV0-KM5YgTKs-Ln2vvBuS867yxObr-ukQ3qyVBSYcBUkRbe13Wkpb1DmlnUOddCradE0SUPEojoF3wQ4AYrXe_ERPmAeWEjUm7DpDvUTtpYyCgbp_IG0xTLh-Dn4cRLTeXotyCsTqBQXpOfjfq4Q5ZN9rWpiz7vHjS6ynCi8N-Udx8-rhZfS7XV5dfVst12XFSp9JoLirS6pa3NTOYUNPUmveyxbyS0ErS4FYKTEnDW9EzIYTpQFMgDXAmTc8uig_3uru5zQ_qIPeqJ7ULdqvDnfLaqtMTZ0c1-B-KM0aIbLLA24NA8N9niEltbdx3qx34OSpKRMOauiYko6__QW_9HFxuT1FKMyNr3PylBj2Bsq73-d5uL6qWXApS4UqyTC3-Q-VlYGvzj0Fvc_6k4M1RwQh6SmP007wfdjwF392DXfAxBugfhkGw2rtPZfepg_sy_ep4fg_sH7uxX9FN1Js</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Wu, Junfeng</creator><creator>Li, Wei</creator><creator>Ning, Jinzhuo</creator><creator>Yu, Weimin</creator><creator>Rao, Ting</creator><creator>Cheng, Fan</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3691-5950</orcidid></search><sort><creationdate>20190101</creationdate><title>Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition</title><author>Wu, Junfeng ; Li, Wei ; Ning, Jinzhuo ; Yu, Weimin ; Rao, Ting ; Cheng, Fan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c615t-da6741bab6b53d012d95a6f8b0648eb8190b8702196b7f3777dcea2e19e638df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antisense RNA</topic><topic>Apoptosis</topic><topic>Autophagy</topic><topic>Biomarkers</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Colorectal cancer</topic><topic>Development and progression</topic><topic>Drug resistance</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Health risk assessment</topic><topic>Immunohistochemistry</topic><topic>Liver cancer</topic><topic>Oncology, Experimental</topic><topic>Original Research</topic><topic>Polymerase chain reaction</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Junfeng</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Ning, Jinzhuo</creatorcontrib><creatorcontrib>Yu, Weimin</creatorcontrib><creatorcontrib>Rao, Ting</creatorcontrib><creatorcontrib>Cheng, Fan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Junfeng</au><au>Li, Wei</au><au>Ning, Jinzhuo</au><au>Yu, Weimin</au><au>Rao, Ting</au><au>Cheng, Fan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>12</volume><spage>495</spage><epage>508</epage><pages>495-508</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer.
Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed.
UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities.
These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>30666128</pmid><doi>10.2147/OTT.S183940</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-3691-5950</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1178-6930 |
ispartof | OncoTargets and therapy, 2019-01, Vol.12, p.495-508 |
issn | 1178-6930 1178-6930 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6331189 |
source | Taylor & Francis Open Access; DOVE Medical Press Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Antisense RNA Apoptosis Autophagy Biomarkers Bladder cancer Cancer Cancer therapies Cell cycle Cell growth Colorectal cancer Development and progression Drug resistance Drug therapy Health aspects Health risk assessment Immunohistochemistry Liver cancer Oncology, Experimental Original Research Polymerase chain reaction Tumorigenesis |
title | Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A26%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20noncoding%20RNA%20UCA1%20targets%20miR-582-5p%20and%20contributes%20to%20the%20progression%20and%20drug%20resistance%20of%20bladder%20cancer%20cells%20through%20ATG7-mediated%20autophagy%20inhibition&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Wu,%20Junfeng&rft.date=2019-01-01&rft.volume=12&rft.spage=495&rft.epage=508&rft.pages=495-508&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S183940&rft_dat=%3Cgale_pubme%3EA687140483%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2229558509&rft_id=info:pmid/30666128&rft_galeid=A687140483&rfr_iscdi=true |